What is the difference between ARA-290 and Ovagen?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Ovagen: Liver-targeted peptide complex modulating hepatocyte gene expression. Supports liver cell regeneration, enzyme function normalization, and hepatic protein synthesis.

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Ovagen FDA approved?

Ovagen is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Ovagen administered in research settings?

In research settings, Ovagen is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Ovagen

Peptide Comparison

ARA-290 vs Ovagen

Name: ARA-290 vs Ovagen — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

16 providers listed

Full ARA-290 profile →

Ovagen

liver peptide bioregulator

LongevityNot EvaluatedResearch Only

1 providers listed

Full Ovagen profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 3 key studies) than Ovagen (Review, 1); both are research compounds.

Quick Verdict

ARA-290

Evidence

Clinical

Half-life

~2 min (IV); ~10–20 min (SC)

Ovagen

Evidence

Review-level

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Oral administration option	Ovagen
More provider options (16 vs 1)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Ovagen

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

—

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

oral, subcutaneous

Availability

Research Only

Providers

16 listed

1 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

—

Research Evidence

ARA-290

ClinicalRCT · 3 key studies · most recent 2026

Ovagen

Review-levelReview · 1 key study · dated evidence base — most recent 2002

Research Citations

ARA-290

Cohort2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

RCT2015 · Molecular Medicine

ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…

Ovagen

Review2002 · Neuroendocrinology Letters

Peptides and ageing

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Ovagen

Liver-targeted peptide complex modulating hepatocyte gene expression. Supports liver cell regeneration, enzyme function normalization, and hepatic protein synthesis.

Research Areas

liver supportdetoxificationhepatic regenerationlongevityanti-aging

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Ovagen

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$5.00/mg

$4.00 – $5.42 range

17 vendors

View price index →Find providers →

Ovagen

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

ARA-290

16 listed

Browse directory →

Providers offering

Ovagen

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Ovagen — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/ara-290/ovagen

https://peptidebase.io/peptides/compare/ara-290/ovagen Methodology License Download JSON Download CSV